Stockreport
Amgen's Q1 Earnings: Solid All Court Progress, Major Weight Loss Catalyst Pending [Seeking Alpha]
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
Non-GAAP EPS fell by 1% YoY to $3.96 per share, and GAAP EPS to $(0.21) owing to underlying Beigene holding and costs related to the Horizon acquisition. Amgen's weight loss drug candidate, MariTide, is showing promising results in Phase 2 trials, management says. Upcoming data represents a major potential upside catalyst. This was a solid set of earnings that seems to show management is successfully future-proofing the company from looming patent expiries. All eyes will be on MariTide, however, and whether Amgen can become a third major player in the mooted +$100bn per annum obesity markets. Investment Overview Amgen ( NASDAQ: AMGN ) announced its Q1'24 earnings earlier today, and the stock price is up over 10% at the time of writing - let's dive into the numbers. The company's revenues increased 22% year-on-year, to $7.45bn, with product sales totaling $7.12bn - also up 22% year-on-year. With cost Recommended For You Recommended For You About AMGN Stock Related
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | AMGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AMGN alerts
AMGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
NEWS
NEWS
- FDA Roundup: May 17, 2024 [Yahoo! Finance][Yahoo! Finance]
- Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC [Yahoo! Finance][Yahoo! Finance]
- U.S. FDA approves Amgen drug for small cell lung cancer [Globe and Mail, The (Toronto, Canada)][Globe and Mail, The]
- FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER[PR Newswire]
- FDA Approves Amgen Drug for Persistently Deadly Form of Lung Cancer [The New York Times][The New York Times]
- More
AMGN
SEC Filings
SEC Filings
- 5/10/24 - Form DEFA14A
- 5/9/24 - Form 4
- 5/9/24 - Form 4
- AMGN's page on the SEC website
- More